Revenues
Revenues in 3Q23 amounted to PLN 50.7 million (-12% y/y). Insulin sales fell 18% y/y.
Declines were seen in both domestic and export sales. The decline in the insulin business was offset by higher revenues from commodity sales - the implementation of new drugs Sitagliptin and ComboDiab, and higher sales of Metformin segment drugs Avamina and Avamina SR (up PLN 5.8 million) and Other PL commodities, including products from the gastrology line (up PLN 4.6 million).
The share of "Gensulin" in the market for classical insulins in Poland at the end of September 2023 was about 34.55%, indicating that Bioton will continue to maintain its position as the market share leader in this segment as measured by sales of the product to pharmacies.
Bioton introduced another oral drug for the treatment of type 2 diabetes, belonging to the DPP-4 inhibitor group, to its portfolio.
